"BioVest" announces its list of the best long-term stocks buys in biotechnology for the month.ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Aug. 12, 1996--The biotechnology investment publication "BioVest" makes its "best buys" in biotechnology stocks announcement for the month. In its upcoming August issue "BioVest" includes Novo Nordisk (NYSE NYSE See: New York Stock Exchange :NVO NVO no visible oestrus (see no visible estrus). Called also NVE. ), ISIS Pharmaceuticals (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :ISIP) and Waters Corp. (NYSE:WAT) as among the best biotech stock buys for long term investment. Findings in recent market research conducted by Delco Scientific Resources, the publisher of "BioVest," indicate that there are now over 300 new biotech drugs in clinical trials -- up over 50 percent from 1994. The fastest growing segments in biotech drug development are in the treatments for HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. , cancer and diseases of the aging (i.e., ALS Als (äls), Ger. Alsen, island, 121 sq mi (313 sq km), Sønderjylland co., S Denmark, in the Lille Bælt, separated from the mainland by the narrow Alensund. , Parkinson's, Alzheimers and diabetes). Biotechnology has been fraught with unrealistic investor expectations. Many biotech investors have been misguided by all the hype and IPO (Initial Public Offering) The first time a company offers shares of stock to the public. While not a computer term per se, many founders, employees and insiders of computer companies have found this acronym more exciting than any tech term they ever heard. madness of the 1980's and 90's. Many biotech companies are now on track with their drug development. "We see a significant increase in treatments being approved under a streamlined FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ," stated BioVest's editor, Steven P. Delco. Delco believes that there has never been a better time to invest in biotechnology. He cautioned however, "There are over 600 public biotech companies in the USA. Investors need the best information available. "I consider the important issues to the long term success for a biotech company to include: The company's prospect for FDA drug approvals and the number of drugs it has in the clinical trial pipeline; the number of FDA approved drugs a company already has; the company's ability to market drugs that it develops; the effectiveness of the company's management team; and the company's competitiveness, the size and growth rate of the markets for its products." Delco continued, "The incubation period for biotechnology has come to an end. The FDA has approved over 39 biotechnology drugs and 23 drugs for the treatment of AIDS. We expect that number of overall biotech drug approvals to double in the next few years." CONTACT: Delco Scientific Resources, Albuquerque Steven Paul Delco, 505/243-0536; fax 505/243-1858 E-mail: delcosci@labmart.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion